ArticleHuman vaccines & immunotherapeutics2025
Exploring parental awareness and willingness to use monoclonal antibodies for respiratory syncytial virus prevention.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) remains a leading cause of severe illness in infancy, and the recent availability of new monoclonal antibodies such as nirsevimab presents an appealing prevention choice. Thus, this study investigated parental awareness, attitude, and acceptability to the application of monoclonal antibody treatment for prevention of RSV among parents in Jordan. In April-June 2025, 597 parents of children aged below 5-years old were surveyed via an online survey. Data analysis was performed using SPSS version 22, logistic regression being employed to examine predictors of acceptance by parents of monoclonal antibody treatment. Over half (330; 55.3%) were aware of RSV, the majority of whom were aware of the most obvious symptoms such as cough (301; 91.2%) and shortness of breath (298; 90.3%). Social media was the best source of information (82.1%). Awareness of monoclonal antibodies was minimal (144; 43.6%), but over half of those who were aware (91; 63.2%) were willing to have their child treated. Altogether, 381 parents (63.9%) believed monoclonal antibodies were effective, and 419 (70.2%) used pediatricians as their primary source of information. The study indicated that female parents, and those who reported believing in monoclonal antibodies effectiveness were more likely to report willingness to use treatment (AOR = 5.161,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.